A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis

Raghu, Ganesh; Brown, Kevin K.; Bradford, Williamson Z.; Starko, Karen M.; Noble, Paul W.; Schwartz, David A.; King, Talmadge E.

doi:10.1056/nejmoa030511

articleNew England Journal of MedicineJan 7, 2004BRONZE OA

A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis

GRGanesh Raghu KKKevin K. Brown WZWilliamson Z. Bradford KMKaren M. Starko PWPaul W. Noble

University of Washington · Seattle University · +5 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

Background

Idiopathic pulmonary fibrosis is a progressive, fatal disease with no known efficacious therapy.

Methods

In a double-blind, multinational trial, we randomly assigned 330 patients with idiopathic pulmonary fibrosis that was unresponsive to corticosteroid therapy to receive subcutaneous interferon gamma-1b or placebo.

Citation impact

652

total citations

FWCI: 51.98
Percentile: 100%
References: 34

Citations per year

Authors

GR
Ganesh RaghuCorresponding
University of Washington, Seattle University
KK
Kevin K. Brown
National Jewish Health, University of Colorado Denver
WZ
Williamson Z. Bradford
InterScience (United States)
KM
Karen M. Starko
InterScience (United States)
PW
Paul W. Noble
Yale University

Topics & keywords

Topics

Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis99%
Lung Cancer Treatments and Mutations0%
Sarcoidosis and Beryllium Toxicity Research0%

Keywords

Medicine
Placebo
Idiopathic pulmonary fibrosis
Pulmonary fibrosis
Internal medicine
Fibrosis
Gastroenterology
Lung

No related works found for this paper.